Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
AI Model Improves Prediction of Knee Osteoarthritis Progression Using MRI and Biomarkers
A new AI-assisted model that combines MRI, biochemical, and clinical data improves predictions of worsening knee osteoarthritis.
•EurekAlert
AI Model Predicts Multiple Genetic Markers from Colorectal Pathology Slides
Researchers developed and validated an AI model that simultaneously detects multiple genetic markers in colorectal cancer tissue slides.
•EurekAlert
Photonic Chip Enables Versatile Neural Networks for Imaging and Speech AI
Chinese scientists have developed a reconfigurable integrated photonic chip capable of running diverse neural networks, including those for image and speech processing, with high efficiency.